The IL-2 therapeutic market is witnessing significant growth driven by escalating cancer treatment demands, autoimmune research breakthroughs, and integration with CAR-T/NK cell technologies. Key market contributors include Novartis (Proleukin), Alkermes, NeoImmuneTech, Eli Lilly, and Nektar Therapeutics. Novel IL-2 engineering approaches and strategic therapeutic combinations are propelling innovation throughout this dynamic immunology field, presenting lucrative opportunities for pharmaceutical and biotechnology enterprises. View detailed IL-2 market intelligence and trends: https://www.delveinsight.com/infographics/interleukin-2-market-forecast?utm_source=infographics&utm_medium=promotion&utm_campaign=kkpr